Welcome to our dedicated page for Azitra news (Ticker: AZTR), a resource for investors and traders seeking the latest updates and insights on Azitra stock.
Azitra Inc. develops clinical-stage precision dermatology therapies built around engineered proteins and topical live biotherapeutic products. Its pipeline includes ATR-12, an engineered S. epidermidis program for Netherton syndrome; ATR-04, an engineered S. epidermidis candidate for EGFR inhibitor-associated rash; and ATR-01, a program targeting ichthyosis vulgaris through delivery of recombinant human filaggrin.
Azitra news commonly covers patent protection, preclinical and clinical program updates, scientific presentations, business results, financing activity, shareholder meeting matters, and NYSE American listing-compliance notices. Company updates also reference its microbial discovery platform, artificial intelligence and machine-learning screening tools, and the use of genetically engineered bacteria and proteins for dermatology applications.
Azitra (NYSE American: AZTR) reported new ex vivo human skin data for its ATR-COSF cosmetic program, a supernatant from engineered S. epidermidis that secretes a recombinant human filaggrin domain (rHDfilaggrin). Multiple-dose experiments in TH2-stimulated healthy skin explants showed increased rHDfilaggrin penetration through the stratum corneum into the stratum granulosum versus prior single-dose work, with higher concentrations when formulated as a 2% lyophilized hydrogel compared with concentrated supernatant alone.
In a second ex vivo model using defatted human skin, ATR-COSF hydrogels containing 0.09–7.5% (w/w) supernatant increased elasticity in a dose-dependent manner, from 1.6-fold to 4.4-fold. A 0.28% (w/w) formulation restored elasticity to levels historically observed in healthy skin, and a 0.3% (w/w) sample showed about twice the elasticity of placebo. Safety testing found the 2% supernatant hydrogel non-irritating and non-corrosive to skin and eyes, supporting its potential as a high-value anti-wrinkle cosmetic ingredient, according to Azitra.
Azitra (NYSE American: AZTR) reported corrected, detailed results from two ex vivo human skin tissue studies for its ATR-COSF cosmetic program, a supernatant formulation containing recombinant human filaggrin domain (rHDfilaggrin) derived from engineered S. epidermidis.
In a repeat‑dose model on TH2‑stimulated healthy skin explants, a 2% lyophilized supernatant hydrogel showed increasing rHDfilaggrin penetration from the stratum corneum into the stratum granulosum with additional applications and was classified as non‑irritating and non‑corrosive to skin and eyes. A second ex vivo model using defatted abdominoplasty skin showed dose‑dependent elasticity gains: 0.09% w/w active increased elasticity 1.6‑fold, 7.5% w/w increased it 4.4‑fold, and 0.28% w/w restored elasticity to levels historically seen in healthy skin. According to Azitra, these data support ATR-COSF’s potential as a high‑value cosmetic ingredient and will inform formulation optimization ahead of a planned human study.
Azitra (NYSE American: AZTR) CEO outlined a strategic reorientation toward programs with nearer-term value milestones, backed by a March 2026 financing of $10.5 million plus up to $21 million from warrant exercises.
Key moves include launching the ATR-COSF cosmetic filaggrin initiative, new recombinant protein programs, continued ATR-04 enrollment, and pausing ATR-12 enrollment to conserve capital, with multiple potential partnering or commercialization opportunities from 2026 onward.
Azitra (NYSE American: AZTR) will present at the 2026 BIO International Convention in San Diego. Cofounder and COO Travis Whitfill, Ph.D., MPH will speak on June 23, 2026, at 4:45 PM PT.
The presentation will cover pipeline progress, including ATR-12 and ATR-04 programs, and a new filaggrin-based protein and peptide initiative for cosmetic and cosmeceutical markets.
Azitra (NYSE American: AZTR) adjourned its 2026 Annual Meeting, first convened June 4, 2026, due to lack of quorum, with only about 17% of eligible shares represented versus the required 33 1/3%. The meeting will reconvene virtually on June 15, 2026, at 11:00 a.m. ET via proxydocs.com/AZTR.
Azitra (NYSE American: AZTR) plans to open its 2026 annual stockholder meeting on June 4, 2026, then immediately adjourn and reconvene it on June 15, 2026 at 11:00 a.m. Eastern Time in virtual format.
The adjournment allows extra time for stockholders of record on April 24, 2026 to receive and submit proxies via mail, internet, telephone, or during the reconvened webcast at www.proxydocs.com/AZTR. Previously submitted proxies remain valid unless changed.
Azitra (NYSE American: AZTR) reported Q1 2026 results and outlined clinical and strategic progress in precision dermatology.
Key updates include adding MD Anderson as an ATR-04 trial site, advancing ATR-12 Phase 1b in Netherton syndrome, launching a filaggrin-based cosmeceutical initiative, new U.S. patent coverage for ATR-12, and pricing up to $10.5 million in private placement financing.
Q1 2026 R&D expenses were $1.6 million, G&A $2.4 million, net loss $3.9 million, and cash $10.1 million.
Azitra (NYSE American: AZTR) announced issuance of U.S. Patent No. 12,606,610 B2 on April 21, 2026, titled "Compositions and Methods for Treatment of Netherton Syndrome with LEKTI Expressing Recombinant Microbes."
The patent covers microbes that secrete LEKTI domains and methods to treat skin diseases and provides broad protection for ATR-12, which is in a Phase 1b trial for Netherton syndrome (≈20,000 patients globally).
Azitra (NYSE American: AZTR) will present preclinical data for ATR-01 at ASGCT 2026 showing ATR01-616 delivers recombinant human filaggrin to skin, reduces transepidermal water loss (TEWL) in ex vivo pig skin (p < 0.001), and restores filaggrin and keratin co-localization in reconstructed human epidermis.
The poster supports advancement toward IND-enabling studies and a planned first-in-human trial in ichthyosis vulgaris.
Azitra (NYSE: AZTR) priced a private placement providing gross proceeds of up to $31.4 million, including initial gross proceeds of $10.5 million and up to an additional $20.9 million upon potential cash exercise of warrants.
The financing issues 10,470 Series A preferred shares, Series B and C warrants exercisable at $0.123 per share, and supports new protein and peptide R&D for cosmetic and cosmeceutical commercialization.